Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow SNY by emailGet an email when SNY pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SNY, unsubscribe in one click. Privacy
📣 What SNY Says Is Next
second half of 2026 · “A first regulatory submission in the US is expected in the second half of 2026, depending on final regulatory feedback.”
Company press release, Jul 30, 2026 · SEC filing
in 2027 · “The results are expected to form the basis for a regulatory submission in China in 2027.”
Company press release, Jul 30, 2026 · SEC filing
second half of 2026 · “The phase 2 study of amlitelimab in celiac disease is ongoing and expected to readout in the second half of 2026.”
Company press release, Jul 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full SNY picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNY and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.